Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET

NeuroImage

Volumn 49, Issue 2, 2010, Pages 1259-1270

  Li, I Hsun ^a,b   Huang, Wen Sheng ^b   Shiue, Chyng Yann ^b   Huang, Ya Yao ^b   Liu, Ren Shyan ^c   Chyueh, San Chong ^c   Hu, Shih Hsiung ^d   Liao, Mei Hsiu ^e   Shen, Lie Hang ^e   Liu, Jiang Chuan ^a   Ma, Kuo Hsing ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d MINISTRY OF JUSTICE   (Taiwan)

^e INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

3,4 Methylenedioxymethamphetamine; 4 18F ADAM; Fluoxetine; Immunohistochemistry; Positron emission tomography; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUOXETINE; N,N DIMETHYL 2 (2 AMINO 4 FLUOROPHENYLTHIO)BENZYLAMINE F 18; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ARTICLE; BRAIN REGION; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG UPTAKE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; SEROTONINERGIC NERVE CELL; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; FLUOXETINE; IMMUNOHISTOCHEMISTRY; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPROTECTIVE AGENTS; PHOTOMICROGRAPHY; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 70949084498     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.07.072     Document Type: Article

References (71)

1. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv. Rev. Psychiatry 12 (2004) 305-320
2. Andringa G., Drukarch B., Bol J.G., de Bruin K., Sorman K., Habraken J.B., and Booij J. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. NeuroImage 26 (2005) 1150-1158
3. Banken J.A. Drug abuse trends among youth in the United States. Ann. N. Y. Acad. Sci. 1025 (2004) 465-471
4. Battaglia G., Yeh S.Y., and De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29 (1988) 269-274
5. Baumann M.H., Wang X., and Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl.) 189 (2007) 407-424
6. Berger U.V., Gu X.F., and Azmitia E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215 (1992) 153-160
7. Bogen I.L., Haug K.H., Myhre O., and Fonnum F. Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem. Int. 43 (2003) 393-400
8. Brust P., Hinz R., Kuwabara H., Hesse S., Zessin J., Pawelke B., Stephan H., Bergmann R., Steinbach J., and Sabri O. In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology 28 (2003) 2010-2019
9. Buchert R., Thomasius R., Nebeling B., Petersen K., Obrocki J., Jenicke L., Wilke F., Wartberg L., Zapletalova P., and Clausen M. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J. Nucl. Med. 44 (2003) 375-384
10. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl.) 100 (1990) 509-514
11. Colado M.I., O'Shea E., Granados R., Murray T.K., and Green A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121 (1997) 889-900
12. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., and Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241 (1987) 338-345
13. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., and Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34 (1992) 262-265
14. Cumming P., Møller M., Benda K., Minuzzi L., Jakobsen S., Jensen S.B., Pakkenberg B., Stark A.K., Gramsbergen J.B., Andreasen M.F., and Olsen A.K. A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on serotonin markers in Göttingen minipig brain. Synapse 61 (2007) 478-487
15. de la Torre R., and Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci. 25 (2004) 505-508
16. 123I]β-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur. Neuropsychopharmacol. 14 (2004) 185-189
17. Ferrington L., Kirilly E., McBean D.E., Olverman H.J., Bagdy G., and Kelly P.A. Persistent cerebrovascular effects of MDMA and acute responses to the drug. Eur. J. Neurosci. 24 (2006) 509-519
18. Fischer C., Hatzidimitriou G., Wlos J., Katz J., and Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J .Neurosci. 15 (1995) 5476-5485
19. 11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
20. Gough B., Ali S.F., Slikker Jr. W., and Holson R.R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39 (1991) 619-623
21. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
22. Hartvig P., Bergström M., Antoni G., and Langstrom B. Positron emission tomography and brain monoamine neurotransmission - entries for study of drug interactions. Curr. Pharm. Des. 8 (2002) 1417-1434
23. Hatzidimitriou G., McCann U.D., and Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci. 19 (1999) 5096-5107
24. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
25. Hesse S., Barthel H., Schwarz J., Sabri O., and Müller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 28 (2004) 547-563
26. Hrometz S.L., Brown A.W., Nichols D.E., and Sprague J.E. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci. Lett. 367 (2004) 56-59
27. Jarkas N., McConathy J., Votaw J.R., Voll R.J., Malveaux E., Camp V.M., Williams L., Goodman R.R., Kilts C.D., and Goodman M.M. Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl. Med. Biol. 32 (2005) 75-86
28. Kish S.J., Furukawa Y., Chang L.J., Tong J., Ginovart N., Wilson A., Houle S., and Meyer J.H. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl. Med. Biol. 32 (2005) 123-128
29. Laruelle M., Baldwin R.M., Malison R.T., Zea-Ponce Y., Zoghbi S.S., al-Tikriti M.S., Sybirska E.H., Zimmermann R.C., Wisniewski G., and Neumeyer J.L. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13 (1993) 295-309
30. Lefebvre M., Marchand M., Horowitz J.M., and Torres G. Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry. Life Sci. 64 (1999) 805-811
31. Lemberger L., Bergstrom R.F., Wolen R.L., Farid N.A., Enas G.G., and Aronoff G.R. Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psychiatry 46 (1985) 14-19
32. Linnet K., Koed K., Wiborg O., and Gregersen N. Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res. 697 (1995) 251-253
33. 18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. NeuroImage 45 (2009) 687-693
34. Ma K.H., Li I.H., Huang W.S., Liu R.S., Shiue C.Y., Shen L.H., Chen H.J., and Liu J.C. Fluoxetine protects MDMA-induced neurotoxicity in rat brain. J. Nucl. Med. 49 Suppl. 1 (2008) 207P [Abstract]
35. Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., and Peters F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol. Lett. 112-113 (2000) 133-142
36. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., and Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352 (1998) 1433-1437
37. 11C]DASB. Neuropsychopharmacology 30 (2005) 1741-1750
38. Mortensen O.V., Kristensen A.S., and Wiborg O. Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J. Neurochem. 79 (2001) 237-247
39. 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl. Med. Biol. 25 (1998) 605-610
40. Nielsen K., Brask D., Knudsen G.M., and Aznar S. Immunodetection of the serotonin transporter protein is a more valid marker for serotonergic fibers than serotonin. Synapse 59 (2006) 270-276
41. Nixdorf W.L., Burrows K.B., Gudelsky G.A., and Yamamoto B.K. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J. Neurochem. 77 (2001) 647-654
42. Oesterheld J.R., Armstrong S.C., and Cozza K.L. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 45 (2004) 84-87
43. Parrott A.C. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50 (2004) 329-335
44. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, Burlington, MA
45. 18F]-ADAM) for imaging serotonin transporters. Appl. Radiat. Isotopes 66 (2008) 625-631
46. Piper B.J., Fraiman J.B., Owens C.B., Ali S.F., and Meyer J.S. Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram. Neuropsychopharmacology 33 (2008) 1192-1205
47. Ramamoorthy S., and Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285 (1999) 763-766
48. 123I]β-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46 (2002) 199-205
49. Reneman L., de Win M.M., van den Brink W., Booij J., and den Heeten G.J. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Psychopharmacol. 20 (2006) 164-175
50. Rudnick G., and Wall S.C. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1817-1821
51. Sanchez V., Camarero J., Esteban B., Peter M.J., Green A.R., and Colado M.I. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 134 (2001) 46-57
52. Sánchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 (1999) 467-489
53. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., and Ricaurte G.A. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Exp. Ther. 264 (1993) 1484-1491
54. Scheffel U., and Ricaurte G.A. Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand?. Brain Res. 527 (1990) 89-95
55. Scheffel U., Szabo Z., Mathews W.B., Finley P.A., Dannals R.F., Ravert H.T., Szabo K., Yuan J., and Ricaurte G.A. In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29 (1998) 183-192
56. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl.) 173 (2004) 242-248
57. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240 (1987) 1-7
58. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., and Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br. J. Psychiatry 175 (1999) 63-69
59. Shankaran M., and Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl.) 147 (1999) 66-72
60. Shankaran M., Yamamoto B.K., and Gudelsky G.A. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 385 (1999) 103-110
61. 18)F-ADAM): an improved PET radioligand for serotonin transporters. J. Nucl. Med. 44 (2003) 1890-1897
62. 18F]fluorophenylthio)benzylamine as a serotonin transporter imaging agent. Appl. Radiat. Isot. 58 (2003) 183-191
63. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 (1998) 427-441
64. Sur C., Betz H., and Schloss P. Immunocytochemical detection of the serotonin transporter in rat brain. Neuroscience 73 (1996) 217-231
65. 11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J. Nucl. Med. 43 (2002) 678-692
66. Trigo J.M., Renoir T., Lanfumey L., Hamon M., Lesch K.P., Robledo P., and Maldonado R. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62 (2007) 669-679
67. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., and Chu T.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47 (1994) 1151-1156
68. Upreti V.V., and Eddington N.D. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. J. Pharm. Sci. 97 (2008) 1593-1605
69. Verrico C.D., Miller G.M., and Madras B.K. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl.) 189 (2007) 489-503
70. Xie T., Tong L., McLane M.W., Hatzidimitriou G., Yuan J., McCann U., and Ricaurte G. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31 (2006) 2639-2651
71. Zhou F.C., Tao-Cheng J.H., Segu L., Patel T., and Wang Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res. 805 (1998) 241-254